IMARC Group has recently released a new research study titled “United States Digital Pathology Market Size, Share, Trends and Forecast by Product, Type, Delivery Model, Application, End User, and Region, 2025-2033” which offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends, and competitive landscape to understand the current and future market scenarios.
Market Overview
The United States digital pathology market size was valued at USD 347.48 Million in 2024 and is projected to reach USD 853.47 Million by 2033, growing at a CAGR of 9.70% during the forecast period 2025-2033. Growth is driven by increasing demand for accurate diagnostic solutions, the rise in telepathology adoption for remote consultations, advancements in AI-driven image analysis, improved workflow efficiency, slide scanner technologies, and favorable government initiatives promoting digital healthcare infrastructure.
Study Assumption Years
- Base Year: 2024
- Historical Year/Period: 2019-2024
- Forecast Year/Period: 2025-2033
United States Digital Pathology Market Key Takeaways
- Current Market Size: USD 347.48 Million (2024)
- CAGR: 9.70%
- Forecast Period: 2025-2033
- The increasing incidence of cancer and chronic diseases necessitates precise diagnostics and pathology services driving market demand.
- Adoption of telepathology enhances remote diagnostics and specialist collaboration.
- AI-powered image analysis tools improve diagnostic accuracy and reduce turnaround times.
- Pharmaceutical companies leverage digital pathology for clinical trials and drug discovery.
- Government initiatives support digital healthcare infrastructure expansion.
- Workflow efficiencies and slide scanner advancements push market growth.
Sample Request Link: https://www.imarcgroup.com/united-states-digital-pathology-market/requestsample
To get more information on this market, Request Sample
United States Digital Pathology Market Growth Factors
The United States digital pathology market is experiencing robust growth, fueled by the rising demand for faster and more accurate diagnostic solutions. Healthcare providers are facing increasing patient volumes, particularly in oncology, where precise and timely pathology assessments are critical. Digital pathology improves diagnostic efficiency by converting traditional glass slides into high-resolution digital images, enabling streamlined workflows and significantly shorter turnaround times. A key development in 2024 was the FDA 510(k) clearance of Proscia’s Concentriq AP-Dx platform, which supports primary diagnosis through whole slide imaging and enhances both diagnostic accuracy and pathologist productivity.
Market expansion is also supported by growing research and drug development activities. Pharmaceutical and biotechnology companies, along with academic institutions, are increasingly adopting digital pathology for preclinical studies, clinical trials, and biomarker discovery. The launch of Prov-GigaPath in 2024—an artificial intelligence model trained on 1.3 billion pathology images through a collaboration between Microsoft, the University of Washington, and Providence—demonstrates the impact of advanced analytics in this field. By predicting gene mutations and treatment responses, this technology is accelerating cancer research and reducing development timelines.
The increasing incidence of cancer and other chronic diseases further drives demand for digital pathology solutions. As pathology remains central to diagnosis and disease management, healthcare systems are investing in advanced tools that enhance precision and operational efficiency. Strategic partnerships, such as the 2024 collaboration between Alverno Laboratories and Ibex Medical Analytics, have introduced AI-enabled diagnostic solutions that improve accuracy and reduce turnaround times for prostate, breast, and gastric biopsy analyses. Collectively, these advancements are strengthening diagnostic capabilities, optimizing laboratory workflows, and helping healthcare providers manage growing diagnostic workloads more effectively.
United States Digital Pathology Market Segmentation
Breakup By Product:
- Scanners: Essential for converting glass slides into high-resolution digital images, scanners advance pathology diagnostics through improved image quality and speed.
- Software: Offers tools for image management, analysis, and sharing; AI integration automates image assessment enhancing precision.
- Storage Systems: Manage vast digital image data with secure, scalable solutions including cloud-based and on-site options.
- Communication Systems: Facilitate seamless data exchange and remote consultations enhancing collaboration among healthcare professionals.
Breakup By Type:
- Human Pathology: Dominant segment, driven by chronic diseases, utilizing AI and telepathology to improve diagnostic accuracy and workflow efficiency.
- Veterinary Pathology: Growing use in animal diagnostics and research, enhancing disease management via digital tools.
Breakup By Delivery Model:
- On-premises: Preferred for data security and compliance; suitable for large healthcare facilities needing reliable performance.
- Hosted: Cloud-based solutions gaining traction for flexibility and cost-effectiveness, enabling remote access and collaboration.
Breakup By Application:
- Training and Education: Interactive digital slides for medical education, enhancing learning and collaboration.
- Consulting Services: Enable expert second opinions and detailed analyses, especially for rare diseases.
- Intraoperative Consultation: Quick tissue examination during surgeries for immediate insights, improving surgical outcomes.
- Routine Diagnostic Consultation Services: Largest application area, enhancing diagnostic accuracy and throughput.
- Others: Includes research applications, clinical studies, and medication discovery facilitating extensive data evaluation.
Breakup By End User:
- Pharmaceutical and Biotechnology Companies: Utilize for drug development, biomarker research, and clinical trials.
- Hospitals and Reference Laboratories: Employ to enhance diagnostic accuracy, workflows, and manage high case volumes.
- Academic and Research Institutes: Depend on digital resources for education and collaborative research.
Regional Insights
The Northeast region is the dominant adopter of digital pathology in the United States, supported by advanced healthcare systems, research institutions, and biotechnology companies. Its high investment in research fosters innovation in diagnostics, thereby improving patient care outcomes. The Midwest, South, and West regions show rising adoption backed by healthcare infrastructure enhancements, telepathology expansion, and technology hubs, respectively.
Speak to an Analyst: https://www.imarcgroup.com/request?type=report&id=20357&flag=C
Recent Developments & News
- June 2024: NYU Langone Health launched a digital pathology program replacing traditional microscopes with high-definition, shareable images, improving collaboration, reducing delays, and integrating AI for enhanced diagnostics to address pathologist shortages.
- June 2024: Sectra introduced a genomics IT module for molecular pathology in collaboration with the University of Pennsylvania Health System, advancing cancer diagnostics through genomic data integration and improved precision care.
Competitive Landscape
Major market participants focus on sophisticated imaging technologies, AI-powered solutions, and cloud systems to enhance precision and efficiency. Key strategies include investments in R&D, strategic partnerships, acquisitions, and compliance with regulations. In 2024, Sectra and Leica Biosystems received FDA clearance for DICOM image use in pathology diagnostics, improving interoperability and workflow.
Key Players
- Proscia
- Microsoft
- University of Washington
- Providence
- Alverno Laboratories
- Ibex Medical Analytics
- Sectra
- Leica Biosystems
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302
